Athenex (ATNX) Earns News Impact Rating of 0.19

News coverage about Athenex (NASDAQ:ATNX) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Athenex earned a news impact score of 0.19 on Accern’s scale. Accern also gave headlines about the company an impact score of 45.2573534956072 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment’s scoring:

Athenex (NASDAQ:ATNX) opened at $17.03 on Friday. Athenex has a 52-week low of $11.21 and a 52-week high of $20.79.

A number of equities analysts have recently issued reports on the company. J P Morgan Chase & Co assumed coverage on Athenex in a research note on Wednesday, October 18th. They issued a “neutral” rating and a $22.20 price target on the stock. Laidlaw assumed coverage on Athenex in a research note on Tuesday, September 19th. They issued a “buy” rating and a $36.00 price target on the stock. Credit Suisse Group assumed coverage on Athenex in a research note on Monday, September 18th. They issued an “outperform” rating and a $25.00 price target on the stock. Finally, Royal Bank Of Canada assumed coverage on Athenex in a research note on Thursday, September 14th. They issued an “outperform” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Athenex presently has an average rating of “Buy” and a consensus target price of $27.64.

WARNING: This story was first published by Community Financial News and is the sole property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.com-unik.info/2017/12/03/athenex-atnx-earns-news-impact-rating-of-0-19.html.

Athenex Company Profile

Athenex, Inc is an oncology pharmaceutical company focused on the development and commercialization of therapies for cancer diseases and supportive therapies. The Company’s technology platform is organized into three categories, including Oral Absorption Platform, Src Kinase Inhibitors and Symptom Therapeutics.

Insider Buying and Selling by Quarter for Athenex (NASDAQ:ATNX)

What are top analysts saying about Athenex Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Athenex Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit